

# Serum neurofilament dynamics predicts neurodegeneration in presymptomatic Alzheimer's disease

Nature Medicine

25, 277-283

DOI: [10.1038/s41591-018-0304-3](https://doi.org/10.1038/s41591-018-0304-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Blood biomarkers in neurology: “a call to arms” for laboratory professionals. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1433-1434.	2.3	6
2	Neurofilaments in pre-symptomatic ALS and the impact of genotype. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 538-548.	1.7	76
3	A Mechanical Brain Damage Framework Used to Model Abnormal Brain Tau Protein Accumulations of National Football League Players. <i>Annals of Biomedical Engineering</i> , 2019, 47, 1873-1888.	2.5	21
4	The current status of blood epigenetic biomarkers for dementia. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 435-457.	6.1	21
5	AD biomarker discovery in CSF and in alternative matrices. <i>Clinical Biochemistry</i> , 2019, 72, 52-57.	1.9	15
6	Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 483-492.	2.4	86
8	Early detection of Alzheimer's disease by peptides from phage display screening. <i>Brain Research</i> , 2019, 1721, 146306.	2.2	7
9	Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3148.	4.1	37
10	A combined miRNA-piRNA signature to detect Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 250.	4.8	74
11	Plasma neurofilament light chain and amyloid- $\beta$ are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 186.	7.2	41
12	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	10.2	128
13	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019, 11, e11170.	6.9	228
14	Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort – a prospective cohort study. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 403.	2.4	6
15	Predicting Alzheimer's disease. <i>BioTechniques</i> , 2019, 67, 146-148.	1.8	2
16	Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1221-1233.	1.9	183
17	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689.	2.4	48
18	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. <i>Cell</i> , 2019, 179, 312-339.	28.9	1,675
19	Long-term iron exposure causes widespread molecular alterations associated with memory impairment in mice. <i>Food and Chemical Toxicology</i> , 2019, 130, 242-252.	3.6	16

#	ARTICLE	IF	CITATIONS
20	Uses for humanised mouse models in precision medicine for neurodegenerative disease. Mammalian Genome, 2019, 30, 173-191.	2.2	22
21	PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	2.7	43
22	Data-Driven Analysis of Age, Sex, and Tissue Effects on Gene Expression Variability in Alzheimer's Disease. Frontiers in Neuroscience, 2019, 13, 392.	2.8	22
23	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. Brain, 2019, 142, 1429-1440.	7.6	36
24	Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegeneration. Frontiers in Neurology, 2019, 10, 205.	2.4	8
25	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. Frontiers in Pharmacology, 2019, 10, 310.	3.5	35
26	Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 338.	2.4	124
27	Biomarkers for Alzheimer's disease beyond amyloid and tau. Nature Medicine, 2019, 25, 201-203.	30.7	34
28	Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease. Brain Science Advances, 2019, 5, 94-105.	0.9	3
29	Current Status of the Vietnam Era Twin Study of Aging (VETSA). Twin Research and Human Genetics, 2019, 22, 783-787.	0.6	23
30	Neuro biomarker levels measured with high-sensitivity digital ELISA differ between serum and plasma. Bioanalysis, 2019, 11, 2087-2094.	1.5	23
31	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Progress in Molecular Biology and Translational Science, 2019, 168, 3-23.	1.7	28
32	Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	30.7	328
33	Profile of neuronal exosomes in HIV cognitive impairment exposes sex differences. Aids, 2019, 33, 1683-1692.	2.2	32
34	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	3.5	46
35	Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. PLoS ONE, 2019, 14, e0226697.	2.5	17
36	Diagnostic biomarkers of Alzheimer's disease: A state-of-the-art review. Biomarkers in Neuropsychiatry, 2019, 1, 100005.	1.0	117
37	An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform. Neurology and Therapy, 2019, 8, 73-82.	3.2	83

#	ARTICLE	IF	CITATIONS
38	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	5.9	23
39	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A $\beta$ -C-reactive protein <sup>™</sup> for psychiatrists and neurologists?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 57-67.	2.3	40
40	Planning later life with dementia: comparing family caregivers <sup>™</sup> perspectives on biomarkers with laypersons <sup>™</sup> attitudes towards genetic testing of dementia prediction. New Genetics and Society, 2020, 39, 52-79.	1.2	3
41	Competitive electrochemical immunosensor for the detection of unfolded p53 protein in blood as biomarker for Alzheimer <sup>™</sup> s disease. Analytica Chimica Acta, 2020, 1093, 28-34.	5.4	40
42	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer's and Dementia, 2020, 16, 262-272.	0.8	47
43	Diagnostics and Therapeutics: The Yin and Yang of Diseases Such as Alzheimer. journal of applied laboratory medicine, The, 2020, 5, 229-231.	1.3	1
44	Roles of vascular risk factors in the pathogenesis of dementia. Hypertension Research, 2020, 43, 162-167.	2.7	33
45	Serum neurofilament light chain in healthy elderly and in patients with age <sup>™</sup> related macular degeneration. Acta Ophthalmologica, 2020, 98, e393-e394.	1.1	5
46	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 97-102.	3.0	31
47	Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. Neurology, 2020, 94, e1181-e1189.	1.1	59
48	SERS <sup>™</sup> -based biosensor for Alzheimer disease evaluation through the fast analysis of human serum. Journal of Biophotonics, 2020, 13, e201960033.	2.3	34
49	Plasma biomarkers of astrocytic and neuronal dysfunction in early <sup>™</sup> and late <sup>™</sup> onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 681-695.	0.8	143
50	CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer's Research and Therapy, 2020, 12, 2.	6.2	86
51	Preserving single cells in space and time for analytical assays. TrAC - Trends in Analytical Chemistry, 2020, 122, 115723.	11.4	4
52	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.1	20
53	Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 9-14.	1.9	22
54	Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 685-689.	1.3	6
55	An update on magnetic resonance imaging markers in AD. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094798.	3.5	6

#	ARTICLE	IF	CITATIONS
56	Trigonelline recovers memory function in Alzheimer's disease model mice: evidence of brain penetration and target molecule. <i>Scientific Reports</i> , 2020, 10, 16424.	3.3	23
57	Linguistic markers predict onset of Alzheimer's disease. <i>EClinicalMedicine</i> , 2020, 28, 100583.	7.1	94
58	Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer's Disease. <i>Neuron</i> , 2020, 108, 801-821.	8.1	132
59	Rethinking monogenic neurological diseases. <i>BMJ</i> , The, 0, , m3752.	6.0	5
60	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	10.8	33
61	Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. <i>Clinics in Laboratory Medicine</i> , 2020, 40, 289-303.	1.4	2
62	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976.	7.9	76
63	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. <i>Journal of Neurochemistry</i> , 2021, 159, 389-402.	3.9	20
64	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, 436-444.	1.1	100
65	Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights. <i>Journal of Personalized Medicine</i> , 2020, 10, 61.	2.5	35
66	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.	7.6	60
67	<i>Gga3</i> deletion and a <i>GGA3</i> rare variant associated with late onset Alzheimer's disease trigger BACE1 accumulation in axonal swellings. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	11
68	Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. <i>Nature Neuroscience</i> , 2020, 23, 1580-1588.	14.8	53
69	Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8661.	4.1	5
70	Sleep, 24-h activity rhythms, and plasma markers of neurodegenerative disease. <i>Scientific Reports</i> , 2020, 10, 20691.	3.3	8
71	Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. <i>Nature Communications</i> , 2020, 11, 6024.	12.8	43
72	Longitudinal analysis of premotor anthropometric and serological markers of Parkinson's disease. <i>Scientific Reports</i> , 2020, 10, 20524.	3.3	0
73	Plasma Total $\alpha$ -Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 401-409.	1.5	11

#	ARTICLE	IF	CITATIONS
74	Nanobiosensors for Non-Amyloidbeta-Tau Biomarkers as Advanced Reporters of Alzheimer's Disease. <i>Diagnostics</i> , 2020, 10, 913.	2.6	1
75	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147.	6.2	23
76	Late-onset vs nonmendelian early-onset Alzheimer disease. <i>Neurology: Genetics</i> , 2020, 6, e512.	1.9	82
77	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	4.0	33
78	Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. <i>Nucleic Acids Research</i> , 2020, 48, 10615-10631.	14.5	69
79	Extracellular Vesicle Proteins and MicroRNAs as Biomarkers for Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020, 11, 663.	2.4	57
80	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease. <i>Journal of Personalized Medicine</i> , 2020, 10, 63.	2.5	13
81	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 95, 143-153.	3.1	34
82	Tracking the potential involvement of metabolic disease in Alzheimer's disease's Biomarkers and beyond. <i>International Review of Neurobiology</i> , 2020, 154, 51-77.	2.0	6
83	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1661-1673.	3.7	27
84	Detecting Alzheimer's Dementia Degree. <i>IEEE Transactions on Cognitive and Developmental Systems</i> , 2022, 14, 116-125.	3.8	3
85	Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	244
86	The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?. <i>Journal of Neurology</i> , 2021, 268, 4607-4629.	3.6	28
89	What Can Person-Centred Care in Dementia Learn from the Recovery Movement?. , 2020, , 202-212.		0
90	Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1996-2009.	3.7	3
91	Elevated plasma neurofilament light in aging reflects brain white matter alterations but does not predict cognitive decline or Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12050.	2.4	20
92	Epidemiology and Mental Health in Old Age. , 2020, , 5-23.		0
94	Young-Onset Dementias. , 2020, , 38-49.		0

#	ARTICLE	IF	CITATIONS
95	Rare and Unusual Dementias. , 2020, , 50-77.		0
96	Mania in Late Life. , 2020, , 78-91.		0
97	Alcohol Misuse in Older People. , 2020, , 92-104.		0
98	Drug Misuse in Older People. , 2020, , 105-115.		0
99	Mental Health in Parkinson's Disease. , 2020, , 116-128.		0
100	The Home Assessment in Old Age Psychiatry. , 2020, , 129-138.		0
101	Driving in Dementia. , 2020, , 139-148.		0
102	Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment. , 2020, , 149-160.		0
103	Biomarkers and the Diagnosis of Preclinical Alzheimer's Disease. , 2020, , 161-172.		0
104	To Scan or Not to Scan. , 2020, , 173-190.		0
105	Supporting Self-Management in Early Dementia. , 2020, , 191-201.		0
106	Psychosocial Interventions in Dementia. , 2020, , 213-222.		0
107	Palliative Care in Dementia. , 2020, , 223-242.		0
108	Review of Treatment for Late-Life Depression. , 2020, , 243-253.		0
109	Reducing the Healthcare Burden of Delirium. , 2020, , 254-265.		0
110	Controlling the Confusion. , 2020, , 266-278.		0
111	Residence Capacity. , 2020, , 305-316.		0
114	Neurofilament light chain in the vitreous humor of the eye. Alzheimer's Research and Therapy, 2020, 12, 111.	6.2	13

#	ARTICLE	IF	CITATIONS
116	Mental Health Laws from All UK Jurisdictions. , 2020, , 279-292.		0
117	Deprivation of Liberty. , 2020, , 293-304.		0
118	Understanding the Person with Dementia. , 2020, , 317-327.		0
119	Microfluidics-Based Systems in Diagnosis of Alzheimer's Disease and Biomimetic Modeling. Micromachines, 2020, 11, 787.	2.9	18
120	The pathway to secondary prevention of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12069.	3.7	5
121	Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomarker Insights, 2020, 15, 117727192095031.	2.5	74
122	Anticoagulants for Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1373-1382.	2.6	15
123	Plasma $\beta$ -III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia. Scientific Reports, 2020, 10, 14271.	3.3	20
124	Biomarkers for Alzheimer's Disease Early Diagnosis. Journal of Personalized Medicine, 2020, 10, 114.	2.5	58
125	Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study. Annals of Neurology, 2020, 88, 1065-1076.	5.3	81
126	The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2020, 15, 45.	10.8	178
127	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. Science Translational Medicine, 2020, 12, .	12.4	64
128	Biomarkers: Our Path Towards a Cure for Alzheimer Disease. Biomarker Insights, 2020, 15, 117727192097636.	2.5	21
129	Blood neurofilament light: a critical review of its application to neurologic disease. Annals of Clinical and Translational Neurology, 2020, 7, 2508-2523.	3.7	132
130	Revisiting atherosclerosis and dementia. Nature Neuroscience, 2020, 23, 691-692.	14.8	17
131	Shared proteomic effects of cerebral atherosclerosis and Alzheimer's disease on the human brain. Nature Neuroscience, 2020, 23, 696-700.	14.8	86
132	Fluid Biomarkers and APOE Status of Early Onset Alzheimer's Disease Variants: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2020, 75, 827-843.	2.6	4
133	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807.	6.1	67



#	ARTICLE	IF	CITATIONS
134	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 60-70.	3.1	35
135	Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3158.	4.1	12
136	Neurofilaments: neurobiological foundations for biomarker applications. <i>Brain</i> , 2020, 143, 1975-1998.	7.6	167
137	Plasma Neurofilament Light Chain as a Translational Biomarker of Aging and Neurodegeneration in Dogs. <i>Molecular Neurobiology</i> , 2020, 57, 3143-3149.	4.0	25
138	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 513-521.	10.2	97
139	Serum neurofilament light chain in FTLT: association with C9orf72, clinical phenotype, and prognosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 903-910.	3.7	17
140	Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value. <i>Frontiers in Neuroscience</i> , 2020, 14, 579.	2.8	37
141	The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 74.	6.2	53
142	Further understanding the connection between Alzheimer's disease and Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1065-1077.	0.8	52
143	Efficient suppression of amyloid- $\beta$ peptide aggregation and cytotoxicity with photosensitive polymer nanodots. <i>Journal of Materials Chemistry B</i> , 2020, 8, 5776-5782.	5.8	11
144	Diagnostic Biomarkers for Alzheimer's Disease Using Non-Invasive Specimens. <i>Journal of Clinical Medicine</i> , 2020, 9, 1673.	2.4	32
145	Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 992-1001.	3.7	25
146	Cohort discovery and risk stratification for Alzheimer's disease: an electronic health record-based approach. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12035.	3.7	8
147	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	4.4	31
148	The CNS-specific proteoglycan, brevican, and its ADAMTS4-cleaved fragment show differential serological levels in Alzheimer's disease, other types of dementia and non-demented controls: A cross-sectional study. <i>PLoS ONE</i> , 2020, 15, e0234632.	2.5	8
149	Neurofilaments in disease: what do we know?. <i>Current Opinion in Neurobiology</i> , 2020, 61, 105-115.	4.2	44
150	Wireless monitoring in the ICU on the horizon. <i>Nature Medicine</i> , 2020, 26, 316-317.	30.7	5
151	Molecular biomarkers in the neurological ICU. <i>Current Opinion in Critical Care</i> , 2020, 26, 1.	3.2	9

#	ARTICLE	IF	CITATIONS
152	Plasma tau, neurofilament light chain and amyloid- $\beta^2$ levels and risk of dementia; a population-based cohort study. <i>Brain</i> , 2020, 143, 1220-1232.	7.6	201
153	Presymptomatic Increase of an Extracellular RNA in Blood Plasma Associates with the Development of Alzheimer's Disease. <i>Current Biology</i> , 2020, 30, 1771-1782.e3.	3.9	32
154	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 30.	6.2	14
155	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1119-1129.	2.6	14
156	Peripheral cytokine and fatty acid associations with neuroinflammation in AD and aMCI patients: An exploratory study. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 679-688.	4.1	19
157	Another step forward in blood-based diagnostics for Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 314-316.	30.7	27
158	Big data-driven precision medicine: Starting the custom-made era of iatrology. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110445.	5.6	19
159	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5989-6001.	7.9	28
160	Identifying Protein Biomarkers in Blood for Alzheimer's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 472.	3.7	7
161	Neurofilament light as a biomarker in traumatic brain injury. <i>Neurology</i> , 2020, 95, e610-e622.	1.1	127
162	The role of innate immunity in Alzheimer's disease. <i>Immunological Reviews</i> , 2020, 297, 225-246.	6.0	70
163	Ethical and Social Implications of Using Predictive Modeling for Alzheimer's Disease Prevention: A Systematic Literature Review. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 923-940.	2.6	5
164	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. <i>EMBO Molecular Medicine</i> , 2020, 12, e11803.	6.9	73
165	On-Chip Detection of the Biomarkers for Neurodegenerative Diseases: Technologies and Prospects. <i>Micromachines</i> , 2020, 11, 629.	2.9	11
166	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. <i>Chemical Society Reviews</i> , 2020, 49, 5446-5472.	38.1	56
167	A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 614.	2.4	38
168	Tracking therapies in MS. <i>Neurology</i> , 2020, 94, 465-466.	1.1	0
169	Neurofilament light and tau in serum after head-impact exposure in soccer. <i>Brain Injury</i> , 2020, 34, 602-609.	1.2	19

#	ARTICLE	IF	CITATIONS
170	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , 2020, 26, 387-397.	30.7	471
171	Short Keynote Paper: Single Molecule Detection of Protein Biomarkers to Define the Continuum From Health to Disease. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 1864-1868.	6.3	7
172	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20.	6.2	32
173	Preclinical biomarkers of prion infection and neurodegeneration. <i>Current Opinion in Neurobiology</i> , 2020, 61, 82-88.	4.2	3
174	Neurofilaments: The C-Reactive Protein of Neurology. <i>Brain Sciences</i> , 2020, 10, 56.	2.3	47
175	A unified model of dementias and age-related neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 365-383.	0.8	13
176	Plasma Neurofilament Light Chain May Be a Biomarker for the Inverse Association Between Cancers and Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 10.	3.4	12
177	Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFTDS. <i>Alzheimer's and Dementia</i> , 2020, 16, 71-78.	0.8	33
178	Co-occurrent Alterations of Alzheimer's Genes and Prostate Cancer Genes in Prostate Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 271-275.	2.0	3
179	Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1285-1294.	2.6	20
180	CNS-Derived Blood Exosomes as a Promising Source of Biomarkers: Opportunities and Challenges. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 38.	2.9	144
181	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. <i>Biochemical Pharmacology</i> , 2020, 177, 113945.	4.4	62
182	Design principles and fundamental understanding of biosensors for amyloid- $\beta$ detection. <i>Journal of Materials Chemistry B</i> , 2020, 8, 6179-6196.	5.8	39
183	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1233-1238.	3.9	22
184	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	10.1	121
185	Integrated analysis and network pharmacology approaches to explore key genes of Xingnaojing for treatment of Alzheimer's disease. <i>Brain and Behavior</i> , 2020, 10, e01610.	2.2	10
186	New fluid biomarkers tracking non-amyloid- $\beta$ and non-tau pathology in Alzheimer's disease. <i>Experimental and Molecular Medicine</i> , 2020, 52, 556-568.	7.7	57
187	Biomarkers for Alzheimer's disease—preparing for a new era of disease-modifying therapies. <i>Molecular Psychiatry</i> , 2021, 26, 296-308.	7.9	205

#	ARTICLE	IF	CITATIONS
188	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	4.1	27
189	Attitudes towards prediction and early diagnosis of late-onset dementia: a comparison of tested persons and family caregivers. <i>Aging and Mental Health</i> , 2021, 25, 832-843.	2.8	18
190	Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer's disease. <i>Sleep</i> , 2021, 44, .	1.1	22
191	Blood neuroexosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage. <i>Alzheimer's and Dementia</i> , 2021, 17, 49-60.	0.8	122
192	The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 97, 10-17.	3.1	18
193	Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. <i>Neurology</i> , 2021, 96, e412-e422.	1.1	52
194	Untangling the association of amyloid- $\beta$ and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021, 144, 310-324.	7.6	123
195	The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117229.	0.6	23
196	Targeted metabolomics study of early pathological features in hippocampus of triple transgenic Alzheimer's disease male mice. <i>Journal of Neuroscience Research</i> , 2021, 99, 927-946.	2.9	17
197	Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. <i>European Journal of Neurology</i> , 2021, 28, 974-981.	3.3	30
198	Blood TDP-43 Combined with Demographics Information Predicts Dementia Occurrence in Community Non-Dementia Elderly. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 301-309.	2.6	2
199	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. <i>Science China Life Sciences</i> , 2021, 64, 926-937.	4.9	12
200	Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients. <i>Journal of Neurotrauma</i> , 2021, 38, 1-43.	3.4	68
201	Biomarcadores en la enfermedad de Alzheimer. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 39-50.	0.2	2
202	Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. <i>Scientific Reports</i> , 2021, 11, 703.	3.3	27
203	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 31, 102749.	2.7	8
204	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2021, 34, 266-274.	3.6	54
205	Gene-Targeting Therapeutics for Neurological Disease: Lessons Learned from Spinal Muscular Atrophy. <i>Annual Review of Medicine</i> , 2021, 72, 1-14.	12.2	26

#	ARTICLE	IF	CITATIONS
206	microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective. <i>Cells</i> , 2021, 10, 113.	4.1	37
207	Novel Diagnostic Tools for Identifying Cognitive Impairment in Dogs: Behavior, Biomarkers, and Pathology. <i>Frontiers in Veterinary Science</i> , 2020, 7, 551895.	2.2	16
208	Application of modern neuroimaging technology in the diagnosis and study of Alzheimer's disease. <i>Neural Regeneration Research</i> , 2021, 16, 73.	3.0	26
209	The Potential of Neurofilament Light as a Biomarker in Alzheimer's Disease. <i>European Neurology</i> , 2021, 84, 6-15.	1.4	13
210	Combining blood-based biomarkers to predict risk for Alzheimer's disease dementia. <i>Nature Aging</i> , 2021, 1, 26-28.	11.6	20
211	Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 74-95.	4.9	16
212	Combination of Serum Neurofilament Light Chain Levels and MRI Markers to Predict Cognitive Function in Ischemic Stroke. <i>Neurorehabilitation and Neural Repair</i> , 2021, 35, 247-255.	2.9	12
213	Proteomic Profiling of Cerebrum Mitochondria, Myelin Sheath, and Synaptosome Revealed Mitochondrial Damage and Synaptic Impairments in Association with 3xTg-AD Mice Model. <i>Cellular and Molecular Neurobiology</i> , 2022, 42, 1745-1763.		9
214	Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. <i>Annals of Neurology</i> , 2021, 89, 952-966.	5.3	36
215	The dazzling rise of neurofilaments: Physiological functions and roles as biomarkers. <i>Current Opinion in Cell Biology</i> , 2021, 68, 181-191.	5.4	38
216	Plasma $\beta$ -secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640.	0.8	10
217	Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. <i>Cells</i> , 2021, 10, 386.	4.1	125
218	Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. <i>Molecular Neurodegeneration</i> , 2021, 16, 10.	10.8	101
219	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. <i>Stroke</i> , 2021, 52, 645-654.	2.0	9
220	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 813-821.	0.8	8
221	A neuronal blood marker is associated with mortality in old age. <i>Nature Aging</i> , 2021, 1, 218-225.	11.6	30
222	Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants. <i>Journal of Neurology</i> , 2021, 268, 2570-2577.	3.6	14
224	Neurodegenerative dementias: screening for major threats to healthy longevity with blood biomarkers. <i>The Lancet Healthy Longevity</i> , 2021, 2, e58-e59.	4.6	1

#	ARTICLE	IF	CITATIONS
225	Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 3084-3094.	4.0	42
226	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e87-e95.	4.6	85
227	Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach. <i>Journal of Neuroscience Research</i> , 2021, 99, 1308-1324.	2.9	16
228	Neurological symptoms and blood neurofilament light levels. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 13-20.	2.1	12
229	Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer's Disease. <i>ACS Nano</i> , 2021, 15, 7357-7369.	14.6	17
230	Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. <i>Nature Communications</i> , 2021, 12, 1816.	12.8	33
231	Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. <i>Molecular Psychiatry</i> , 2021, 26, 5955-5966.	7.9	30
232	Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease. <i>Proteomics - Clinical Applications</i> , 2021, 15, e2000072.	1.6	5
233	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 86.	6.2	19
234	Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19. <i>Journal of Neurology</i> , 2021, 268, 3969-3974.	3.6	16
235	Alzheimer's Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4805.	4.1	13
236	Silk Fibroin As an Immobilization Matrix for Sensing Applications. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 2015-2042.	5.2	27
237	Neurofilament light chain as novel blood biomarker of disturbed neuroaxonal integrity in patients with ketamine dependence. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 713-721.	2.6	14
238	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.1	52
239	Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. <i>Journal of Neurology</i> , 2021, 268, 3835-3844.	3.6	14
240	Cerebral Microbleeds, Cerebrospinal Fluid, and Neuroimaging Markers in Clinical Subtypes of Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 543866.	2.4	7
241	Association of plasma neurofilament L (NfL) levels with severity of dementia in Alzheimer's disease: An exploratory study from South India. <i>Asian Journal of Psychiatry</i> , 2021, 58, 102606.	2.0	1
242	Predictive value of serum neurofilament light chain for persistent cognitive deficits in elderly depressive patients. <i>Journal of Affective Disorders Reports</i> , 2021, 4, 100095.	1.7	1

#	ARTICLE	IF	CITATIONS
243	Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging. <i>Alzheimer's and Dementia</i> , 2022, 18, 88-102.	0.8	65
244	Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 19-32.	2.6	3
245	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. <i>Frontiers in Neuroscience</i> , 2021, 15, 672954.	2.8	19
246	Association of accelerated long-term forgetting and senescence-related blood-borne factors in asymptomatic individuals from families with autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 107.	6.2	10
247	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 659898.	3.4	9
248	Plasma phosphatidylcholines and vitamin B12/folate levels are possible prognostic biomarkers for progression of Alzheimer's disease. <i>Experimental Gerontology</i> , 2021, 147, 111264.	2.8	13
249	A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 101.	6.2	17
250	Biomarkers and Their Implications in Alzheimer's Disease: A Literature Review. <i>Exploratory Research and Hypothesis in Medicine</i> , 2021, 000, 000-000.	0.4	5
251	Neurofilament light: a narrative review on biomarker utility. <i>Faculty Reviews</i> , 2021, 10, 46.	3.9	23
252	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021, 27, 1034-1042.	30.7	236
253	Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage. <i>Current Neuropharmacology</i> , 2022, 20, 713-737.	2.9	8
254	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.8	23
255	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 521-534.	11.6	64
256	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	1.9	30
257	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster A $\beta$ -associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 103-115.	0.8	24
258	Biomarkers for neurodegenerative diseases. <i>Nature Medicine</i> , 2021, 27, 954-963.	30.7	399
259	Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia. <i>Neurobiology of Disease</i> , 2021, 153, 105311.	4.4	39
260	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A $\beta$ <sub>42</sub> /A $\beta$ <sub>40</sub> and p-tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293.	0.8	72



#	ARTICLE	IF	CITATIONS
261	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021, 12, 3555.	12.8	115
262	Serum neurofilament light chain as a severity marker for spinocerebellar ataxia. <i>Scientific Reports</i> , 2021, 11, 13517.	3.3	11
263	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	12.8	219
264	Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 550-565.	11.6	21
265	The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population. <i>Scientific Reports</i> , 2021, 11, 13438.	3.3	6
266	Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A $\beta$ -PET and cognition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1289-1295.	1.9	29
267	Dementia Experts on Why the FDA Approval of Aducanumab for Alzheimer's Gets Mixed Grades. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2021, 21, 1,17-19.	0.0	0
269	Network Analysis Identifies Sex-Specific Gene Expression Changes in Blood of Amyotrophic Lateral Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7150.	4.1	12
270	Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer's Disease in the FIT-AD Trial. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 601-611.	2.2	4
271	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589.	10.1	144
272	Biological age in healthy elderly predicts aging-related diseases including dementia. <i>Scientific Reports</i> , 2021, 11, 15929.	3.3	35
273	Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 705989.	3.4	9
274	Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 718959.	3.4	10
275	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	10.2	26
276	Aging: What We Can Learn From Elephants. <i>Frontiers in Aging</i> , 2021, 2, .	2.6	5
277	Artificial Intelligence for Alzheimer's Disease: Promise or Challenge?. <i>Diagnostics</i> , 2021, 11, 1473.	2.6	38
278	Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases. <i>Current Neuropharmacology</i> , 2021, 19, 1273-1303.	2.9	28
279	Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 951-964.	2.6	5



#	ARTICLE	IF	CITATIONS
280	Evaluate and Optimize Cell-Free RNA Extraction Methods to Apply for Alzheimer's Disease Biomarkers Detection. IFMBE Proceedings, 2022, , 591-609.	0.3	0
281	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology, 2021, 97, e1466-e1474.	1.1	20
282	Phenotyping Alzheimer's disease with blood tests. Science, 2021, 373, 626-628.	12.6	21
283	Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimer's Research and Therapy, 2021, 13, 137.	6.2	59
284	Advances in Genetic and Molecular Understanding of Alzheimer's Disease. Genes, 2021, 12, 1247.	2.4	9
285	Microglial inclusions and neurofilament light chain release follow neuronal $\alpha$ -synuclein lesions in long-term brain slice cultures. Molecular Neurodegeneration, 2021, 16, 54.	10.8	20
286	Cortical Thickness and Serum NFL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis. Neurology: Neuroimmunology and Neuroinflammation, 2021, 8, .	6.0	25
287	Plasma neurofilament light as a potential biomarker for cognitive decline in a longitudinal study of middle-aged urban adults. Translational Psychiatry, 2021, 11, 436.	4.8	21
288	Plasma NFL levels and longitudinal change rates in <i>C9orf72</i> and <i>GRN</i> -associated diseases: from tailored references to clinical applications. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1278-1288.	1.9	25
289	Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. Brain, 2022, 145, 105-118.	7.6	18
290	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. Neurodegenerative Disease Management, 2021, 11, 329-340.	2.2	4
291	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurology, The, 2021, 20, 605-614.	10.2	29
292	Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 1117-1127.	2.8	21
293	The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer's disease patients. Alzheimer's Research and Therapy, 2021, 13, 161.	6.2	15
294	Mutations in the Amyloid- $\beta$ Protein Precursor Reduce Mitochondrial Function and Alter Gene Expression Independent of 42-Residue Amyloid- $\beta$ Peptide. Journal of Alzheimer's Disease, 2021, 83, 1039-1049.	2.6	5
295	Loss of presenilin function enhances tau phosphorylation and aggregation in mice. Acta Neuropathologica Communications, 2021, 9, 162.	5.2	10
296	Factors associated with dropout in the longitudinal Vogel study of cognitive decline. European Journal of Neuroscience, 2022, 56, 5587-5600.	2.6	2
297	Blood Neurofilament Light Chain in Genetic Ataxia: A Meta-Analysis. Movement Disorders, 2022, 37, 171-181.	3.9	8

#	ARTICLE	IF	CITATIONS
298	Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1938-1949.	0.8	9
299	The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases. <i>Journal of Neuroscience Methods</i> , 2021, 361, 109281.	2.5	14
300	SMI-32 labeling in Cajal-Retzius cells of feline primary visual cortex. <i>Neuroscience Letters</i> , 2021, 762, 136165.	2.1	1
301	Neuroimaging and biomarker evidence of neurodegeneration in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 589-598.e6.	2.9	24
302	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1141-1154.	0.8	89
303	Biomarkers of Diseases: Their Role in Emergency Medicine. , 0, , .		0
304	Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population. <i>Clinical Chemistry</i> , 2021, 67, 1628-1639.	3.2	20
306	Early-Onset Alzheimer's Disease: What Is Missing in Research?. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 4.	4.2	88
307	Plasma Neurofilament Light Combined with Risk Genes for the Diagnosis of Alzheimer's Disease. , 0, 83, .		1
308	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12099.	2.4	16
309	<scp>CSF NFL</scp> in a Longitudinally Assessed <scp>PD</scp> Cohort: Age Effects and Cognitive Trajectories. <i>Movement Disorders</i> , 2020, 35, 1138-1144.	3.9	36
310	NfL and pNfH are increased in Friedreich's ataxia. <i>Journal of Neurology</i> , 2020, 267, 1420-1430.	3.6	17
311	Major risk factors for Alzheimer's disease: age and genetics. <i>Lancet Neurology</i> , The, 2020, 19, 475-476.	10.2	12
312	On the phantom-like appearance of bilingualism effects on neurocognition: (How) should we proceed?. <i>Bilingualism</i> , 2021, 24, 197-210.	1.3	66
313	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. <i>Nature Communications</i> , 2020, 11, 812.	12.8	316
324	Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 533-538.	1.5	7
325	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 118.	6.2	129
326	Biomarkers in Alzheimer's disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 27-37.	0.2	13

#	ARTICLE	IF	CITATIONS
327	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. Revista Brasileira De Psiquiatria, 2020, 42, 431-441.	1.7	42
328	Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. Aging, 2019, 11, 6904-6914.	3.1	34
329	Serum neurofilament light chain rate of change in Alzheimer's disease: potentials applications and notes of caution. Annals of Translational Medicine, 2019, 7, S133-S133.	1.7	8
330	Genome-wide association study of cerebrospinal fluid neurofilament light levels in non-demented elders. Annals of Translational Medicine, 2019, 7, 657-657.	1.7	15
331	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues in Clinical Neuroscience, 2019, 21, 177-191.	3.7	17
332	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1721.	3.0	2
333	Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease. Journal of Stroke, 2020, 22, 369-376.	3.2	27
334	Preparation of a small-size superconducting joint for C-doped 30-filament MgB <sub>2</sub> wires. Superconductor Science and Technology, 2021, 34, 125009.	3.5	6
335	Electrochemical Immunosensor for the Sensitive Detection of Alzheimer's Biomarker Amyloid $\beta$ (1-42) Using the Heme $\alpha$ -amyloid $\beta$ (1-42) Complex as the Signal Source. Electroanalysis, 2022, 34, 263-274.	2.9	8
336	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
337	Neurochemical Markers of Traumatic Brain Injury: Relevance to Acute Diagnostics, Disease Monitoring, and Neuropsychiatric Outcome Prediction. Biological Psychiatry, 2022, 91, 405-412.	1.3	17
338	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	7.6	38
339	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	6.9	29
340	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
341	Extracellular Vesicle Proteins and MicroRNAs Are Linked to Chronic Post-Traumatic Stress Disorder Symptoms in Service Members and Veterans With Mild Traumatic Brain Injury. Frontiers in Pharmacology, 2021, 12, 745348.	3.5	18
343	Aus den Biowissenschaften. Nachrichten Aus Der Chemie, 2019, 67, 50-50.	0.0	0
346	Novel Blood Biomarkers for an Earlier Diagnosis of Alzheimer's Disease: A Literature Review. International Journal of Medical Students, 0, , .	0.5	0
348	Association of the Level of Neurofilament Light With Disease Severity in Patients With Spinocerebellar Ataxia Type 2. Neurology, 2021, 97, .	1.1	16

#	ARTICLE	IF	CITATIONS
349	Plasma neurofilament L to amyloid $\beta$ 242 ratio in differentiating Alzheimer's type from non-Alzheimer's dementia: A cross-sectional pilot study from India. Asian Journal of Psychiatry, 2021, 66, 102914.	2.0	4
350	BMI and Allostatic Load Are Directly Associated with Longitudinal Increase in Plasma Neurofilament Light among Urban Middle-Aged Adults. Journal of Nutrition, 2022, 152, 535-549.	2.9	12
351	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum $\tau$ and $\alpha$ syn: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
352	Ultrasensitive detection of blood biomarkers of Alzheimer's and Parkinson's diseases: a systematic review. Biomarkers in Medicine, 2021, 15, 1693-1708.	1.4	2
355	Intermittent hypoxia treatment alleviates memory impairment in the 6-month-old APPswe/PS1dE9 mice and reduces amyloid beta accumulation and inflammation in the brain. Alzheimer's Research and Therapy, 2021, 13, 194.	6.2	10
356	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	10.2	360
358	Serum neurofilament light chain level as a predictor of cognitive stage transition. Alzheimer's Research and Therapy, 2022, 14, 6.	6.2	19
359	VII. Fluid Biomarkers for Neurological Diseases: Focusing on Blood-based Biomarkers. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 2502-2508.	0.0	0
360	CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis. Neurology: Neuroimmunology and Neuroinflammation, 2022, 9, .	6.0	10
361	Functional brain activity constrained by structural connectivity reveals cohort-specific features for serum neurofilament light chain. Communications Medicine, 2022, 2, .	4.2	2
363	Associations of risk genes with onset age and plasma biomarkers of Alzheimer's disease: a large case-control study in mainland China. Neuropsychopharmacology, 2022, 47, 1121-1127.	5.4	5
364	Toward Pre-Diagnostic Detection of Dementia in Primary Care. Journal of Alzheimer's Disease, 2022, 86, 479-490.	2.6	1
365	Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO Journal, 2022, 41, e109108.	7.8	38
366	Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers. Alzheimer's Research and Therapy, 2022, 14, 9.	6.2	2
367	Exosomal MicroRNA-Based Predictive Model for Preclinical Alzheimer's Disease: A Multicenter Study. Biological Psychiatry, 2022, 92, 44-53.	1.3	11
368	Diagnostic Blood Biomarkers in Alzheimer's Disease. Biomedicines, 2022, 10, 169.	3.2	13
369	Challenges and hopes for Alzheimer's disease. Drug Discovery Today, 2022, 27, 1027-1043.	6.4	87
370	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of Disease, 2022, 166, 105662.	4.4	21

#	ARTICLE	IF	CITATIONS
371	Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes. <i>European Journal of Neurology</i> , 2022, 29, 1630-1642.	3.3	9
372	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 26.	6.2	49
373	Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 778955.	2.9	4
374	Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature. <i>Alzheimer's and Dementia</i> , 2022, 18, 1687-1693.	0.8	24
375	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1957-1968.	0.8	2
376	Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer's disease: results from ADNI. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 2363-2372.	2.9	5
377	Characteristics of serum neurofilament light chain as a biomarker in hereditary spastic paraplegia type 4. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 326-338.	3.7	6
378	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 1598-1609.	7.6	17
379	Blood and brain gene expression signatures of chronic intermittent ethanol consumption in mice. <i>PLoS Computational Biology</i> , 2022, 18, e1009800.	3.2	6
380	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2687-2698.	0.8	13
381	A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease. <i>Brain Communications</i> , 2022, 4, fcac045.	3.3	17
383	Biobanking and Biomarkers in the Alzheimer's Disease Drug-Development Ecosystem. , 2022, , 123-134.		0
385	New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 2292-2307.	0.8	14
386	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. <i>Diagnostics</i> , 2022, 12, 796.	2.6	4
387	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	10.2	210
388	Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria. <i>Medicina (Lithuania)</i> , 2022, 58, 433.	2.0	5
389	The bidirectional lung brain-axis of amyloid- $\beta^2$ pathology: ozone dysregulates the peri-plaque microenvironment. <i>Brain</i> , 2023, 146, 991-1005.	7.6	17
390	Key Disease Mechanisms Linked to Amyotrophic Lateral Sclerosis in Spinal Cord Motor Neurons. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 825031.	2.9	7

#	ARTICLE	IF	CITATIONS
391	Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives. Neuroscience Bulletin, 2022, 38, 677-691.	2.9	24
392	Nontransgenic Guinea Pig Strains Exhibit Hallmarks of Human Brain Aging and Alzheimer's Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 1766-1774.	3.6	4
393	Neurofilament Light Chain (NF-L) Stimulates Lipid Peroxidation to Neuronal Membrane through Microglia-Derived Ferritin Heavy Chain (FTH) Secretion. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-8.	4.0	3
394	Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer's Disease Drug Discovery. , 2022, , 106-122.		0
395	Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Neurology, 2022, 269, 4270-4280.	3.6	30
396	Development of Fluid Biomarkers for Alzheimer's Disease. , 2022, , 361-374.		0
397	Statistical Considerations in the Design and Analysis of Alzheimer's Disease Clinical Trials. , 2022, , 232-248.		0
398	Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers. Biomedicines, 2022, 10, 850.	3.2	19
399	Plasma Neurofilament Light and Glial Fibrillary Acidic Protein Levels over Thirty Days in a Porcine Model of Traumatic Brain Injury. Journal of Neurotrauma, 2022, 39, 935-943.	3.4	5
400	Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study. Journal of Alzheimer's Disease, 2022, 86, 1243-1254.	2.6	6
401	Relationship Between Plasma Neurofilament Light Chain, Gut Microbiota, and Dementia: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2022, 86, 1323-1335.	2.6	5
402	Tauopathies: new perspectives and challenges. Molecular Neurodegeneration, 2022, 17, 28.	10.8	91
403	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
404	Neurofilament light chain and disease activity in patients with multiple sclerosis. Neurologie Pro Praxi, 2021, 22, 212-216.	0.1	0
405	Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA). Breast Cancer Research and Treatment, 2022, 192, 65-74.	2.5	8
406	Blood-based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	6.9	122
407	Altered protein secretion in Batten disease. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	16
408	Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview. Current Pharmaceutical Design, 2022, 28, .	1.9	4

#	ARTICLE	IF	CITATIONS
409	Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram Syndrome. <i>Frontiers in Neuroscience</i> , 2022, 16, 795317.	2.8	2
413	Blood biomarkers for Alzheimer's disease and related disorders. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 51-55.	2.1	28
414	Amyloid $\beta$ protein and MicroRNA $\beta$ 84 in NCAM $\beta$ -labeled exosomes from peripheral blood are potential diagnostic markers for Alzheimer's disease. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 1093-1107.	3.9	14
415	Advances in the development of new biomarkers for Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2022, 11, 25.	8.0	65
416	Effect of Race on Prediction of Brain Amyloidosis by Plasma A $\beta$ 42/A $\beta$ 40, Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, .	1.1	63
417	Neurofilaments as Decay Rate Biomarker in Spinocerebellar Ataxia Type 1. <i>Neurology</i> , 2022, 98, 821-822.	1.1	2
418	Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1517-1526.	2.6	8
419	Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. <i>Frontiers in Neuroscience</i> , 2022, 16, 837390.	2.8	12
421	Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis. <i>Biomedicines</i> , 2022, 10, 1077.	3.2	6
422	A Real-Time Sensing System for Monitoring Neural Network Degeneration in an Alzheimer's Disease-on-a-Chip Model. <i>Pharmaceutics</i> , 2022, 14, 1022.	4.5	5
423	Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy. <i>Annals of Neurology</i> , 2022, 92, 358-363.	5.3	5
424	Plasma neurofilament light and its association with all-cause mortality risk among urban middle-aged men and women. <i>BMC Medicine</i> , 2022, 20, .	5.5	4
425	MRI and laboratory monitoring of disease-modifying therapy efficacy and risks. <i>Current Opinion in Neurology</i> , 2022, 35, 278-285.	3.6	5
426	Linking Plasma Amyloid Beta and Neurofilament Light Chain to Intracortical Myelin Content in Cognitively Normal Older Adults. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	2
428	Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
429	MicroRNA-29c-3p in dual-labeled exosome is a potential diagnostic marker of subjective cognitive decline. <i>Neurobiology of Disease</i> , 2022, 171, 105800.	4.4	11
430	Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update. <i>Journal of</i>		



#	ARTICLE	IF	CITATIONS
432	Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation?. <i>Seminars in Immunology</i> , 2022, 59, 101628.	5.6	13
433	Plasma neurofilament light chain: A biomarker predicting severity in patients with acute ischemic stroke. <i>Medicine (United States)</i> , 2022, 101, e29692.	1.0	5
434	Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 0, , .	3.7	7
435	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE- $\epsilon$ 4 in female patients with Alzheimer's disease. <i>Nature Aging</i> , 2022, 2, 616-634.	11.6	11
437	Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease. <i>Brain Science Advances</i> , 2019, 5, 94-105.	0.9	0
438	Amyloid- $\beta$ misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years. <i>Alzheimer's and Dementia</i> , 2023, 19, 1020-1028.	0.8	23
439	Alzheimer's disease: a scoping review of biomarker research and development for effective disease diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 681-703.	3.1	5
440	Ultrasensitive detection of multiple Alzheimer's disease biomarkers by SERS-LFA. <i>Analyst</i> , The, 2022, 147, 4124-4131.	3.5	11
441	The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2669-2686.	0.8	169
442	Neurofilament light levels predict clinical progression and death in multiple system atrophy. <i>Brain</i> , 2022, 145, 4398-4408.	7.6	17
443	Plasma A $\beta$ 42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 1117-1134.	0.8	44
444	An accurate fully automated panel of plasma biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 1204-1215.	0.8	45
445	Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 1890.	3.2	9
446	Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1913-1926.	3.0	11
447	Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	7
448	Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease. <i>Biomedicines</i> , 2022, 10, 1869.	3.2	9
449	Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	9
450	Associations of sensory and motor function with blood-based biomarkers of neurodegeneration and Alzheimer's disease in midlife. <i>Neurobiology of Aging</i> , 2022, 120, 177-188.	3.1	7



#	ARTICLE	IF	CITATIONS
451	Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 1946.	3.2	14
453	Earlier Alzheimer's disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading. <i>Nature Communications</i> , 2022, 13, .	12.8	20
454	Neurofilament light chain in central nervous system infections: a prospective study of diagnostic accuracy. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
455	Neurofilaments in neurologic disorders and beyond. <i>Journal of the Neurological Sciences</i> , 2022, 441, 120380.	0.6	5
456	Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 119, 1-7.	3.1	5
457	Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2195-2205.	3.9	10
458	Ultrasensitive monitoring of SARS-CoV-2-specific antibody responses based on a digital approach reveals one week of IgG seroconversion. <i>Biosensors and Bioelectronics</i> , 2022, 217, 114710.	10.1	2
459	Development of a digital anti-Müllerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment. <i>Talanta</i> , 2023, 253, 123970.	5.5	1
460	Highly Sensitive Serum Protein Analysis Using Magnetic Bead-Based Proximity Extension Assay. <i>Analytical Chemistry</i> , 2022, 94, 12481-12489.	6.5	3
461	A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 363-380.	2.6	8
462	Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1832-1837.	3.7	21
463	Multipronged diagnostic and therapeutic strategies for Alzheimer's disease. <i>Chemical Science</i> , 2022, 13, 13657-13689.	7.4	25
464	NREM sleep loss increases neurofilament light chain levels in APP/PS1 and C57BL/6J mice. <i>Sleep and Breathing</i> , 2023, 27, 1495-1504.	1.7	1
465	Plasma neurofilament light as blood marker for poor brain white matter integrity among middle-aged urban adults. <i>Neurobiology of Aging</i> , 2023, 121, 52-63.	3.1	4
466	Neurofilaments contribution in clinic: state of the art. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	9
467	Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of patients with diabetes based on their cognitive status. <i>Diabetes Research and Clinical Practice</i> , 2022, 193, 110121.	2.8	4
469	Fluid biomarkers in Alzheimer's disease. <i>Advances in Clinical Chemistry</i> , 2023, , 249-281.	3.7	7
470	Blood-based biomarkers in Alzheimer's disease: a mini-review. <i>Metabolic Brain Disease</i> , 2023, 38, 185-193.	2.9	5

#	ARTICLE	IF	CITATIONS
471	Distinct brain pathologies associated with Alzheimer's disease biomarker-related phospho-tau 181 and phospho-tau 217 in <i>App</i> knock-in mouse models of amyloid- $\beta$ amyloidosis. <i>Brain Communications</i> , 2022, 4, .	3.3	5
472	Current and Future Trends in Biomarkers for the Early Detection of Alzheimer's Disease in Asia: Expert Opinion. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 699-710.	2.2	3
473	Maximizing treatment efficacy through patient stratification in neuropathic pain trials. <i>Nature Reviews Neurology</i> , 2023, 19, 53-64.	10.1	17
474	Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample. <i>Neurology</i> , 2023, 100, e874-e883.	1.1	4
475	Experimental evidence for temporal uncoupling of brain $\text{A}\beta$ deposition and neurodegenerative sequelae. <i>Nature Communications</i> , 2022, 13, .	12.8	6
476	The role of neurofilament light in genetic frontotemporal lobar degeneration. <i>Brain Communications</i> , 2022, 5, .	3.3	6
477	Functional network segregation is associated with attenuated tau spreading in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 2034-2046.	0.8	10
478	Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment. <i>Cell</i> , 2022, 185, 5028-5039.e13.	28.9	45
479	Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease. <i>Annals of Neurology</i> , 2023, 93, 819-829.	5.3	4
480	Nano-biosensors for Diagnosing Infectious and Lifestyle-Related Disease of Human: An Update. , 2023, , 79-103.		0
481	Axonal degeneration in the anterior insular cortex is associated with Alzheimer's co-pathology in Parkinson's disease and dementia with Lewy bodies. <i>Translational Neurodegeneration</i> , 2022, 11, .	8.0	5
482	Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis. <i>Journal of Neurology</i> , 2023, 270, 1908-1930.	3.6	6
483	Digital detection of proteins. <i>Lab on A Chip</i> , 2023, 23, 818-847.	6.0	13
484	Plasma biomarker profiles in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2023, 146, 1132-1140.	7.6	19
485	Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer's disease. <i>Brain</i> , 2023, 146, 2928-2943.	7.6	4
486	Blood Biomarkers for Alzheimer's Dementia Diagnosis. <i>Korean Journal of Clinical Laboratory Science</i> , 2022, 54, 249-255.	0.3	0
487	Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with $\text{A}\beta$ -PET, neurodegeneration, and cognition. <i>Alzheimer's and Dementia</i> , 2023, 19, 2790-2804.	0.8	7
488	Androgen Deprivation Therapy Unrelated to Alzheimer's Disease in the UK Biobank Cohort. <i>Anticancer Research</i> , 2023, 43, 437-440.	1.1	2

#	ARTICLE	IF	CITATIONS
489	Predicting progression to Alzheimer's disease with human hippocampal progenitors exposed to serum. Brain, 2023, 146, 2045-2058.	7.6	7
491	Serum neurofilament light chain in functionally relevant coronary artery disease and adverse cardiovascular outcomes. Biomarkers, 2023, 28, 341-351.	1.9	0
492	Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease. Chinese Medical Journal, 2023, 136, 505-521.	2.3	4
493	Early Detection of Alzheimer's Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers. Journal of Alzheimer's Disease, 2023, 92, 1077-1091.	2.6	3
494	A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. EBioMedicine, 2023, 89, 104456.	6.1	6
495	Association of polysialic acid serum levels with schizophrenia spectrum and bipolar disorder-related structural brain changes and hospitalization. Scientific Reports, 2023, 13, .	3.3	1
497	Systemic inflammatory markers in patients with polyneuropathies. Frontiers in Immunology, 0, 14, .	4.8	6
499	Early Diagnosis of Alzheimer's Disease: Moving Toward a Blood-Based Biomarkers Era. Clinical Interventions in Aging, 0, Volume 18, 353-358.	2.9	0
500	Plasma amyloid beta 40/42, phosphorylated tau 181, and neurofilament light are associated with cognitive impairment and neuropathological changes among World Trade Center responders: A prospective cohort study of exposures and cognitive aging at midlife. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
501	Association between rest-activity rhythm and cognitive function in the elderly: The U.S. National Health and Nutrition Examination Survey, 2011-2014. Frontiers in Endocrinology, 0, 14, .	3.5	3
503	Cerebrospinal fluid YKL-40 level evolution is associated with autoimmune encephalitis remission. Clinical and Translational Immunology, 2023, 12, .	3.8	0
504	Serum neurofilament light chain in patients with epilepsy and cognitive impairment. Epileptic Disorders, 2023, 25, 229-236.	1.3	0
505	Review on Alzheimer Disease Detection Methods: Automatic Pipelines and Machine Learning Techniques. Sci, 2023, 5, 13.	3.0	12
507	Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. Brain, 2023, 146, 2570-2583.	7.6	7
508	Protein biomarkers in multiple sclerosis. Encephalitis, 2023, 3, 54-63.	0.3	2
509	Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges. Acta Neuropathologica, 2023, 145, 515-540.	7.7	13
510	Plasma NFL is associated with the APOE $\epsilon$ 4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults. Alzheimer's Research and Therapy, 2023, 15, .	6.2	7
511	Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders. Nature Communications, 2023, 14, .	12.8	7

#	ARTICLE	IF	CITATIONS
512	Blood neurofilament light chain in Parkinson's disease. Journal of Neural Transmission, 2023, 130, 755-762.	2.8	6
513	Gamma neuromodulation improves episodic memory and its associated network in amnesic mild cognitive impairment: a pilot study. Neurobiology of Aging, 2023, 129, 72-88.	3.1	3
514	Application Value of Serum Neurofilament Light Protein for Disease Staging in Huntington's Disease. Movement Disorders, 2023, 38, 1307-1315.	3.9	0
515	Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice. Journal of Alzheimer's Disease Reports, 2023, 7, 355-380.	2.2	8
516	The association between personality and plasma biomarkers of astrogliosis and neuronal injury. Neurobiology of Aging, 2023, 128, 65-73.	3.1	5
517	Sennoside A restrains TRAF6 level to modulate ferroptosis, inflammation and cognitive impairment in aging mice with Alzheimer's Disease. International Immunopharmacology, 2023, 120, 110290.	3.8	3
518	Urinary di-(2-ethylhexyl) phthalate metabolites are independently related to serum neurofilament light chain, a biomarker of neurological diseases, in adults: results from NHANES 2013-2014. Environmental Science and Pollution Research, 2023, 30, 66417-66425.	5.3	0
519	Plasma tau and neurofilament light chain as biomarkers of Alzheimer's disease and their relation to cognitive functions. Journal of Medicine and Life, 2023, 16, 284-289.	1.3	0
520	Improving the Accuracy, Robustness, and Dynamic Range of Digital Bead Assays. Analytical Chemistry, 2023, 95, 8613-8620.	6.5	1
521	Blood and CSF Biomarkers in Autosomal Dominant Cerebellar Ataxias. Contemporary Clinical Neuroscience, 2023, , 379-392.	0.3	0
522	Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 4127-4138.	0.8	3
523	Recent Advances in Photoelectrochemical Sensing of Alzheimer's Biomarkers. Biochip Journal, 2023, 17, 218-229.	4.9	0
524	Blood-Based Proteomic Profiling Identifies Potential Biomarker Candidates and Pathogenic Pathways in Dementia. International Journal of Molecular Sciences, 2023, 24, 8117.	4.1	3
525	Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2023, 13, 485-499.	2.8	2
526	Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study. Journal of Neurology, 2023, 270, 4248-4261.	3.6	1
527	Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nature Aging, 2023, 3, 506-519.	11.6	36
528	Translating blood biomarkers into clinical practice for Alzheimer's disease: Challenges and perspectives. Alzheimer's and Dementia, 2023, 19, 4226-4236.	0.8	0
530	Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 10523.	4.1	3

#	ARTICLE	IF	CITATIONS
531	Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN). <i>Nature Neuroscience</i> , 2023, 26, 1449-1460.	14.8	4
533	Truncated TDP43 proteoforms diagnostic of frontotemporal dementia with TDP43 pathology. <i>Alzheimer's and Dementia</i> , 2024, 20, 103-111.	0.8	1
534	A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer's disease. <i>Genome Medicine</i> , 2023, 15, .	8.2	2
535	Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11624.	4.1	7
536	Emergence delirium and postoperative delirium associated with high plasma NfL and GFAP: an observational study. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
537	Serum Neurofilament Light Chain in the Diagnostic Evaluation of Patients with Cognitive Symptoms in the Neurological Consultation of a Tertiary Center. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-7.	2.6	0
538	Inflammation affects dynamic functional network connectivity pattern changes via plasma NFL in cognitive impairment patients. <i>CNS Neuroscience and Therapeutics</i> , 2024, 30, .	3.9	1
539	Influence of N6-methyladenosine (m6A) modification on cell phenotype in Alzheimer's disease. <i>PLoS ONE</i> , 2023, 18, e0289068.	2.5	0
540	Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease. <i>Nature Medicine</i> , 2023, 29, 1979-1988.	30.7	24
542	Biomarkers of aging in frailty and age-associated disorders: State of the art and future perspective. <i>Ageing Research Reviews</i> , 2023, 91, 102044.	10.9	7
543	Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia. <i>Alzheimer's and Dementia</i> , 2023, 19, 5860-5871.	0.8	6
544	Association between urinary glyphosate levels and serum neurofilament light chain in a representative sample of US adults: NHANES 2013-2014. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 0, , .	3.9	2
545	Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations. <i>Cureus</i> , 2023, , .	0.5	0
546	The Role of Clinical Assessment in the Era of Biomarkers. <i>Neurotherapeutics</i> , 2023, 20, 1001-1018.	4.4	1
547	Neurological manifestations of post-acute sequelae of COVID-19: which liquid biomarker should we use?. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	3
548	Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology. <i>Clinical Chemistry</i> , 0, , .	3.2	0
549	Neurofilament Light Chain in Aqueous Humor as a Marker of Neurodegeneration in Glaucoma. <i>Clinical Ophthalmology</i> , 0, Volume 17, 2209-2217.	1.8	1
550	Application of biomarker-derived fluorescent probes for the detection of Alzheimer's disease. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 169, 117369.	11.4	2

#	ARTICLE	IF	CITATIONS
551	Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study. European Journal of Neurology, 2024, 31, .	3.3	0
552	Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis. 2024. 31, 1-11.	3.0	5
553	The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease. Brain, 2024, 147, 12-25.	7.6	4
554	Neurofilaments â€“ Small proteins of physiological significance and predictive power for future neurodegeneration and cognitive decline across the life span. Ageing Research Reviews, 2023, 90, 102037.	10.9	3
555	Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3. DMM Disease Models and Mechanisms, 2023, 16, .	2.4	0
556	Plasma Neurofilament Light Chains as Blood-Based Biomarkers for Early Diagnosis of Canine Cognitive Dysfunction Syndrome. International Journal of Molecular Sciences, 2023, 24, 13771.	4.1	0
557	Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy. EBioMedicine, 2023, 96, 104781.	6.1	3
558	Late blood levels of neurofilament light correlate with outcome in patients with traumatic brain injury. Journal of Neurotrauma, 0, , .	3.4	1
560	Alzheimer's disease: From immunotherapy to immunoprevention. Cell, 2023, 186, 4260-4270.	28.9	17
561	Clinical, imaging, and biomarker evidence of amyloid- and tau-related neurodegeneration in late-onset epilepsy of unknown etiology. Frontiers in Neurology, 0, 14, .	2.4	2
562	Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes. Brain, 2024, 147, 936-948.	7.6	0
563	Association Between Serum Neurofilament Light Chain and Cognitive Performance Among Older Adults in the United States: A Cross-Sectional Study. Neurology and Therapy, 0, , .	3.2	0
564	Plasma biomarkers predict Alzheimerâ€™s disease before clinical onset in Chinese cohorts. Nature Communications, 2023, 14, .	12.8	3
565	Comparison of CSF and plasma NfL and pNfH for Alzheimerâ€™s disease diagnosis: a memory clinic study. Journal of Neurology, 2024, 271, 1297-1310.	3.6	1
566	Application value of plasma Neurofilament light combined with magnetic resonance imaging to comprehensively evaluate multiple sclerosis activity and status. Frontiers in Neurology, 0, 14, .	2.4	0
567	Specific serum autoantibodies predict the development and progression of Alzheimerâ€™s disease with high accuracy. Brain, Behavior, and Immunity, 2024, 115, 543-554.	4.1	0
568	Serum neurofilament light chain and cognition decline in <sc>US</sc> elderly: A cross-sectional study. Annals of Clinical and Translational Neurology, 2024, 11, 17-29.	3.7	1
569	Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics. Alzheimer's and Dementia, 2024, 20, 1436-1458.	0.8	1

#	ARTICLE	IF	CITATIONS
570	Correlation Studies of Hippocampal Morphometry and Plasma NFL Levels in Cognitively Unimpaired Subjects. IEEE Transactions on Computational Social Systems, 2023, 10, 3602-3608.	4.4	0
572	The use of ATR-FTIR spectroscopy for the diagnosis of Alzheimer's disease using oral buccal cells. Applied Spectroscopy Reviews, 0, , 1-15.	6.7	0
573	Nano-Brush Structure for Rapid Label-Free Differentiation of Alzheimer's Disease Stages and Direct Capture of Neuron-Derived Exosomes from Human Blood Plasma. ACS Applied Materials & Interfaces, 2023, 15, 56478-56489.	8.0	0
574	Cell-free RNA signatures predict Alzheimer's disease. IScience, 2023, 26, 108534.	4.1	0
575	Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases. Journal of Alzheimer's Disease, 2023, 96, 1623-1638.	2.6	0
576	Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease. Expert Review of Molecular Diagnostics, 2023, 23, 1153-1165.	3.1	0
577	Florbetapir PET-assessed demyelination is associated with faster tau accumulation in an APOE $\epsilon 4$ -dependent manner. European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51, 1035-1049.	6.4	0
579	Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis. Brain, 2024, 147, 627-636.	7.6	0
580	Identification and validation of supervariants reveal novel loci associated with human white matter microstructure. Genome Research, 2024, 34, 20-33.	5.5	0
581	Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers. Frontiers in Human Neuroscience, 0, 17, .	2.0	0
582	Biomarkers for Alzheimer's Disease. , 2023, , 63-92.		0
583	Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative. Alzheimer's and Dementia, 0, , .	0.8	0
584	Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease. Molecular Neurodegeneration, 2023, 18, .	10.8	0
585	High-Performance Plasma Biomarker Panel for Alzheimer's Disease Screening Using a Femtomolar-Level Label-Free Biosensing System. ACS Nano, 2024, 18, 2117-2130.	14.6	1
587	Biomarkers in Alzheimer's Disease: Are Olfactory Neuronal Precursors Useful for Antemortem Biomarker Research?. Brain Sciences, 2024, 14, 46.	2.3	0
588	Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments. Bioengineering, 2024, 11, 45.	3.5	0
589	Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease. International Journal of Molecular Sciences, 2024, 25, 1231.	4.1	0
590	Normative Values for Serum Neurofilament Light Chain in US Adults. Journal of Clinical Neurology		



#	ARTICLE	IF	CITATIONS
591	A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups. <i>Alzheimer's and Dementia</i> , 2024, 20, 2000-2015.	0.8	0
592	Plasma neurofilament light as a promising biomarker in neuronal intranuclear inclusion disease. <i>Journal of Neurology</i> , 2024, 271, 2042-2052.	3.6	0
593	Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2024, 10, .	5.3	0
594	Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review. <i>Biomolecules</i> , 2024, 14, 93.	4.0	0
595	Serum LDL Promotes Microglial Activation and Exacerbates Demyelinating Injury in Neuromyelitis Optica Spectrum Disorder. <i>Neuroscience Bulletin</i> , 0, , .	2.9	0
596	Graphene as basis of biological sensors for determining markers of neurodegenerative dementia. <i>Medical Alphabet</i> , 2024, , 28-33.	0.2	0
597	Digging into the intrinsic capacity concept: Can it be applied to Alzheimer's disease?. <i>Progress in Neurobiology</i> , 2024, 234, 102574.	5.7	0
598	Age Prediction Using Resting-State Functional MRI. <i>Neuroinformatics</i> , 2024, 22, 119-134.	2.8	0
600	Novel Development and Prospects in Pathogenesis, Diagnosis, and Therapy of Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2024, 8, 345-354.	2.2	0
601	Temporal serum neurofilament light chain concentrations in sheep inoculated with the agent of classical scrapie. <i>PLoS ONE</i> , 2024, 19, e0299038.	2.5	0
602	Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings. <i>Methods in Molecular Biology</i> , 2024, , 3-14.	0.9	0
603	Biomarkers for Alzheimer's Disease – An Overview. <i>Macromolecular Symposia</i> , 2024, 413, .	0.7	0
604	Blood-based CNS regionally and neuronally enriched extracellular vesicles carrying pTau217 for Alzheimer's disease diagnosis and differential diagnosis. <i>Acta Neuropathologica Communications</i> , 2024, 12, .	5.2	0
605	Bead-based microfluidic platforms for multiplex and ultrasensitive immunoassays in clinical diagnosis and treatment. , 2024, 2, 100063.		0
606	Childhood obesity and risk of Alzheimer's disease: a Mendelian randomization study. <i>Archives of Public Health</i> , 2024, 82, .	2.4	0
607	Clinical Accuracy of Serum Neurofilament Light to Differentiate Frontotemporal Dementia from Primary Psychiatric Disorders is Age-Dependent. <i>American Journal of Geriatric Psychiatry</i> , 2024, , .	1.2	0
609	Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls. <i>Molecular Psychiatry</i> , 0, , .	7.9	0
610	Neurofilaments Light Chain in Neurodegenerative Dementias: A Review of Imaging Correlates. <i>Brain Sciences</i> , 2024, 14, 272.	2.3	0